Common cholesterol drug tested as potential cancer fighter
NCT ID NCT07213557
Summary
This study is testing if adding a common cholesterol-lowering drug, simvastatin, to standard first-line treatment helps control advanced stomach and esophageal cancer. It will enroll 84 patients who have a specific genetic change (ARID1A mutation) and have not had prior treatment. The goal is to see if the combination keeps the cancer from growing for a longer time compared to standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC GASTROOESOPHAGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.